← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › ANTIMETABOLITES › Pyrimidine analogues
decitabine
L01BC08
Forms & Strengths
- Lyophilized powder for injection: 50 mg per vial
Adult Dosing
- Myelodysplastic syndromes (MDS): 15 mg/m² intravenously over 3 hours every 8 hours for 3 consecutive days, repeated every 6 weeks
- Alternative schedule: 20 mg/m² intravenously over 1 hour daily for 5 consecutive days, repeated every 4 weeks
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS
- Treatment of acute myeloid leukemia (off-label or in specific combination regimens)
Mechanism of Action
- Hypomethylating agent that inhibits DNA methyltransferases after incorporation into DNA
- Causes hypomethylation of DNA and cellular differentiation or apoptosis in dysfunctional hematopoietic cells
Contraindications
- Known hypersensitivity to decitabine
Adverse Reactions
- Neutropenia
- Thrombocytopenia
- Anemia
- Pyrexia
- Fatigue
- Nausea and vomiting
- Cough
- Constipation
- Diarrhea
- Hyperglycemia
Drug Interactions
- Live vaccines: Risk of severe infections; concomitant use is not recommended
- Myelosuppressive agents: May potentiate bone marrow suppression; monitor blood counts closely
Curated Content: Needs Vetting Before Put to Clinical Use